Tirzepatide reduces albuminuria in patients with type 2 diabetes: post-hoc pooled analysis of SURPASS 1-5

被引：0
|
作者：
Wiese, R. J. [1 ]
Heerspink, H. J. L. [2 ]
Tuttle, K. R. [3 ]
Pavo, I. [1 ]
Haupt, A. [1 ]
Yang, Z. [1 ]
Hemmingway, A. [1 ]
Cherney, D. Z. I. [4 ]
Sattar, N. [5 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[3] Univ Washington, Providence Hlth Care, Spokane, WA USA
[4] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Div Nephrol,Dept Med, Toronto, ON, Canada
[5] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [1] Tirzepatide Reduces Albuminuria in Patients with T2D-Post Hoc Pooled Analysis of SURPASS 1-5
    Heerspink, Hiddo L.
    Tuttle, Katherine R.
    Pavo, Imre
    Haupt, Axel
    Yang, Zhengyu
    Wiese, Russell
    Hemmingway, Andrea
    Cherney, David
    Sattar, Naveed
    DIABETES, 2023, 72
  • [2] Tirzepatide as a Novel Therapeutic Option for Patients with Type 2 Diabetes: A Pooled Analysis of Subgroups of SURPASS 1-5 Trials
    Abdalla, Mohammed Altigani
    Soyiri, Ireneous
    Atkin, Stephen
    Sathyapalan, Thozhukat
    JOURNAL OF DIABETOLOGY, 2023, 14 (02) : 65 - 73
  • [3] COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4
    Nicholls, Stephen J.
    D'Alessio, David
    Wiese, Russell
    Pavo, Imre
    Zeytinoglu, Meltem
    Romera, Irene
    Weerakkody, Govinda J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1628 - 1628
  • [4] Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials
    Apperloo, Ellen M.
    Tuttle, Katherine R.
    Pavo, Imre
    Haupt, Axel
    Taylor, Rebecca
    Wiese, Russell J.
    Hemmingway, Andrea
    Cherney, David Z. I.
    Sattar, Naveed
    Heerspink, Hiddo J. L.
    DIABETES CARE, 2025, 48 (03)
  • [5] Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies
    Wilding, J. P. H.
    Kwan, A. Y. M.
    Maldonado, J. M.
    Wang, H.
    Rasouli, N.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S289 - S289
  • [6] Post Hoc Analysis of SURPASS-1 to-5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
    De Block, Christophe
    Peleshok, Jennifer
    Wilding, John P. H.
    Kwan, Anita Y. M.
    Rasouli, Neda
    Maldonado, Juan M.
    Wysham, Carol
    Liu, Minzhi
    Aleppo, Grazia
    Benneyworth, Brian D.
    DIABETES THERAPY, 2025, 16 (01) : 43 - 71
  • [7] Effect of tirzepatide in GADA-positive individuals with type 2 diabetes: a post hoc analysis of the SURPASS 2-5 trials
    Buzzetti, R.
    Peters, A. L.
    Lee, C. J.
    Pavo, I.
    Liu, M.
    Paik, J. S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S312 - S312
  • [8] Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials
    Rasouli, Neda
    Wilding, John P. H.
    Kwan, Anita Y. M.
    Paik, Jim S.
    Sharma, Palash
    Peleshok, Jennifer
    DIABETES THERAPY, 2025, 16 (04) : 701 - 715
  • [9] Tirzepatide Induces Weight Loss in Patients with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through-5 Studies
    Kwan, Anita
    Maldonado, Juan M.
    Wang, Hui
    Rasouli, Neda
    Wilding, John
    DIABETES, 2022, 71
  • [10] Tirzepatide leads to significant improvement in postprandial glycaemic control in people with type 2 diabetes (SURPASS 1-5)
    Lee, C. J.
    Spanakis, E.
    Bray, R.
    Brown, K.
    Billings, L. K.
    Chivukula, K.
    Rodriguez, A.
    Giorgino, F.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S300 - S301
12345